<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789620</url>
  </required_header>
  <id_info>
    <org_study_id>KEK_155_08</org_study_id>
    <nct_id>NCT00789620</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Lidocaine on Transperitoneal Laparoscopic Urological Surgery</brief_title>
  <official_title>Effects of Intravenous Lidocaine on Transperitoneal Laparoscopic Urological Surgery: A Prospective, Randomised, Placebo Controlled, Double-blind, Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effective perioperative analgesia is the key to postoperative rehabilitation. An intriguing&#xD;
      body of evidence suggests that short-term administration of intravenous lidocaine may produce&#xD;
      pain relief that far exceeds both the duration of infusion and the half-life of the drug.&#xD;
      When pain relief is provided, concomitant anal-gesic medication can be reduced, side effects&#xD;
      from pain relieving medication minimized with a potential for a more rapid postoperative&#xD;
      recovery and less complications. IV application of lidocaine should de-crease the duration of&#xD;
      bowel dysfunction. We hypothesise that i.v. application of lidocaine in a standard&#xD;
      antiarrythmic dose can significantly improve acute rehabilitation after laparoscopic&#xD;
      urological surgery and so shorten the hospital stay (primary outcome). We expect that the&#xD;
      intraoperative inflammatory response can significantly be reduced.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective perioperative analgesia is the key to postoperative rehabilitation. It has been&#xD;
      suggested that a decrease in postoperative pain and opioid use ameliorates the return of&#xD;
      normal bowel function after general surgery. Conventional analgesic treatment involves the&#xD;
      use of intravenous, oral and transdermal formulations of drugs. Repetitive administration is&#xD;
      required for sustained pain relief. Common side effects (postoperative nausea and vomiting,&#xD;
      postoperative ileus) of these analgesics may have a detrimental effect on postoperative&#xD;
      recovery and led to a prolonged hospital stay. An intriguing body of evidence suggests that&#xD;
      short-term administration of intravenous lidocaine may produce pain relief that by far&#xD;
      exceeds both the duration of the infusion and the half-life of the drug thus reducing&#xD;
      concomitant analgesic medication can be reduced and its side effects enabling a more rapid&#xD;
      postoperative recovery with less complications. Lidocaine is a commonly used local anesthetic&#xD;
      and an antiarrythmic agent. It has been shown to preserve neuroelectric function in animal&#xD;
      experiments. Intraoperative administration of lidocaine in a standard antiarrythmic dose has&#xD;
      been shown to decrease the occurrence of cognitive dysfunction in the early postoperative&#xD;
      period after coronary artery bypass surgery. Lidocaine can induce a significant re-duction of&#xD;
      several components of chronic pain in patients with poststroke or spinal cord injury related&#xD;
      pain. Sodium channel blockers (e.g. lidocaine) are approved for intravenous administration in&#xD;
      the treat-ment of neuropathic pain states. In addition lidocaine has anti-inflammatory&#xD;
      properties and preclinical studies have suggested antihyperalgesic effects on the peripheral&#xD;
      and central nervous system. Lidocaine decreases the minimum alveolar concentration (MAC) of&#xD;
      inhaled anesthetics and has been used clinically to reduce the requirements for other&#xD;
      anesthetic drugs. IV application of lidocaine is said to decrease the duration of bowel&#xD;
      dysfunction and postoperative pain intensity.&#xD;
&#xD;
      We hypothesise that i.v. application of lidocaine in a standard antiarrythmic dose can&#xD;
      significantly improve acute rehabilitation after laparoscopic urological surgery and so&#xD;
      shorten the hospital stay. We expect that the intraoperative inflammatory response can&#xD;
      significantly be reduced.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>end of hospitalisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in pain score</measure>
    <time_frame>2 and 4 h postop and 3*/d on day 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in fatigue score</measure>
    <time_frame>2 and 4 h postop and 3*/d on day 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PONV</measure>
    <time_frame>2 and 4 h postop and 3*/d on day 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first episode of flatus and defecation</measure>
    <time_frame>2 and 4 h postop and 3*/d on day 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in metabolic and inflammatory responses (cortisol, glc, CRP and procalcitonin)</measure>
    <time_frame>preoperatively and on day 1 and 2 in the morning</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Pain</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lidocaine 1% administrated as a bolus of 1.5 mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% as a bolus 1.5mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  ASA 1 to 3&#xD;
&#xD;
          -  Laparoscopic transperitoneal urological surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver insufficiency&#xD;
&#xD;
          -  Steroid therapy&#xD;
&#xD;
          -  Chronic opioid therapy&#xD;
&#xD;
          -  Allergy to lidocaine&#xD;
&#xD;
          -  Pre-existing disorder of the gastrointestinal tract&#xD;
&#xD;
          -  AV-block II-III, sinusbradycardia, heart insufficiency, long QT-syndrome&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Y Wüthrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Anesthesiology and pain service, Bern University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of Urology, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <last_update_submitted>March 23, 2011</last_update_submitted>
  <last_update_submitted_qc>March 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Patrick Y Wüthrich MD</name_title>
    <organization>Dep. of anesthesiology and pain service, Bern University Hospital</organization>
  </responsible_party>
  <keyword>intravenous lidocaine</keyword>
  <keyword>laparoscopic urological surgery</keyword>
  <keyword>hospital stay</keyword>
  <keyword>pain</keyword>
  <keyword>fatigue</keyword>
  <keyword>length of stay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

